AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZNGet Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is £118.05 ($145.72).

AZN has been the topic of several recent research reports. Barclays reaffirmed an “overweight” rating and set a £135 ($166.65) target price on shares of AstraZeneca in a research note on Tuesday, September 12th. UBS Group upgraded shares of AstraZeneca to a “buy” rating in a research note on Wednesday, July 12th. Morgan Stanley increased their price target on shares of AstraZeneca from £127 ($156.77) to £129 ($159.24) in a research note on Monday, September 25th. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Monday, October 2nd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, July 10th.

View Our Latest Research Report on AZN

AstraZeneca Stock Performance

LON:AZN opened at £102.76 ($126.85) on Tuesday. The company has a debt-to-equity ratio of 82.30, a current ratio of 0.87 and a quick ratio of 0.59. The firm has a market capitalization of £159.28 billion, a price-to-earnings ratio of 3,161.85, a PEG ratio of 0.47 and a beta of 0.16. The company’s 50-day moving average is £107.37 and its two-hundred day moving average is £111.04. AstraZeneca has a 1-year low of £100.20 ($123.69) and a 1-year high of £123.92 ($152.97).

AstraZeneca Company Profile

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.